This article is more than 5 years old. Information may no longer be current.

Envisia Therapeutics launches with $25 million in financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Envisia Therapeutics, a biotechnology company formed by Liquidia Technologies, is being launched with $25 million in Series A financing, according to a news release.

ENV515, Envisia’s lead product, is an extended-release formulation of a prostaglandin analogue with the potential to provide sustained reduction of IOP for several months after one dose, the release said.

Envisia is also using its Particle Replication in Non-Wetting Templates (PRINT) technology to create a new line of small- and large-molecule particle-based ocular therapeutics.

Investors in Envisia include Canaan Partners, New Enterprise Associates, Pappas Ventures, Morningside Technology Ventures and Wakefield Group. Funding will be devoted to advancing ENV515 and other products in development.